The Government of Pakistan has ordered a review of the existing drug pricing formula to ensure medicines remain reasonably priced, warning that price hikes without valid justification will not be accepted.
Chairing a Drug Regulatory Authority of Pakistan (DRAP) meeting, Economic Affairs Minister Ahad Cheema instructed officials to expedite pending pricing cases after being informed that their case-by-case evaluation was near completion. He emphasized a pricing mechanism that prioritizes patient accessibility without placing unnecessary hurdles on pharmaceutical companies and importers.
The Pakistan Pharmaceutical Manufacturers Association (PPMA) urged the government to consult industry stakeholders during the review. PPMA highlighted that rising costs of imported active ingredients, energy, freight, and foreign exchange exposure make long-term price freezes unviable for domestic manufacturers.
Read the full story on the original publisher’s website.
Open original article